17 abr 2018 año - FDA is hosting a public meeting on Patient-
Focused Drug Development for Opioid Use
Disorder (OUD), in collaboration with National
Institute of Drug Abuse (NIDA). In addition to
NIDA, FDA is also working closely with patient
advocacy and community organizations to
encourage participation from individuals with
OUD. This meeting aligns with FDA’s ongoing
work aimed at reducing the impact of opioid
abuse and addiction.
